301. Association Between Optimal Combination Pharmacotherapy and Survival After Stroke: A Registry and Pharmaceutical Dispensing Study
- Author
-
Dominique A Cadilhac, Helen M Dewey, Lachlan L. Dalli, Vijaya Sundararajan, Amanda G. Thrift, Frank M Sanfilippo, Monique F Kilkenny, Rohan Grimley, Joosup Kim, and Nadine E. Andrew
- Subjects
medicine.medical_specialty ,Information Systems and Management ,Proportional hazards model ,business.industry ,Hazard ratio ,Health Informatics ,Disease ,medicine.disease ,Lower risk ,Pharmacotherapy ,lcsh:HB848-3697 ,Internal medicine ,Antithrombotic ,Cohort ,medicine ,lcsh:Demography. Population. Vital events ,business ,Stroke ,Information Systems ,Demography - Abstract
IntroductionTo prevent further vascular events, prescribing of multiple classes of medications (antihypertensive, antithrombotic and lipid-lowering) is recommended in national clinical guidelines following ischaemic stroke. Objectives and ApproachUsing real-world data, we determined the association between optimal combination pharmacotherapy (supply of all three classes, “optimal pharmacotherapy”) and survival after stroke. We linked a cohort of patients with first-ever ischaemic stroke from the Australian Stroke Clinical Registry (2010-2014) with national pharmaceutical dispensing and national mortality data. Cox regression was used to determine associations between pharmacotherapy in the first 30 days of stroke with 1-year (from day 31 to 395) all-cause mortality. All analyses were adjusted for socio-demographic (age, sex) and clinical characteristics (stroke severity, discharge destination). ResultsAmong 6684 patients discharged following first-ever ischaemic stroke (median length-of-stay 5 days), 6466 patients who survived to 30 days were included (44% female, median age 74 years). During the first 30 days from discharge, 71.4% received ≥1 medication class, and 32.9% (n=2125) received optimal pharmacotherapy. Patients with optimal pharmacotherapy were older (≥75 years 50.3% vs
- Published
- 2020